Clinical performance evaluation of the Fluorecare® SARS-CoV-2 & Influenza A/B & RSV rapid antigen combo test in symptomatic individuals

Jean-Louis Bayart; Constant Gillot; Jean-Michel Dogné; Gatien Roussel; Valérie Verbelen; Julien Favresse; Jonathan Douxfils

doi:10.1016/j.jcv.2023.105419

Clinical performance evaluation of the Fluorecare® SARS-CoV-2 & Influenza A/B & RSV rapid antigen combo test in symptomatic individuals

Jean-Louis Bayart, Constant Gillot, Jean-Michel Dogné, Gatien Roussel, Valérie Verbelen, Julien Favresse, Jonathan Douxfils

Résultats de recherche: Contribution à un journal/une revue › Article › Revue par des pairs

36 Téléchargements (Pure)

Résumé

BACKGROUND: A SARS-CoV-2+Flu A/B+RSV Combo Rapid test may be more relevant than Rapid Antigen Diagnostic (RAD) tests targeting only SARS-CoV-2 since we are facing a concurrent circulation of these viruses during the winter season.

OBJECTIVES: To assess the clinical performance of a SARS-CoV-2+Flu A/B+RSV Combo test in comparison to a multiplex RT-qPCR.

STUDY DESIGN: Residual nasopharyngeal swabs issued from 178 patients were included. All patients, adults and children, were symptomatic and presented at the emergency department with flu-like symptoms. Characterization of the infectious viral agent was done by RT-qPCR. The viral load was expressed as cycle threshold (Ct). Samples were then tested using the multiplex RAD test Fluorecare ®ฏ SARS-CoV-2 & Influenza A/B & RSV Antigen Combo Test. Data analysis was carried out using descriptive statistics.

RESULTS: The sensitivity of the test varies according to the virus, with the highest sensitivity observed for Influenza A (80.8.% [95%CI: 67.2 - 94.4]) and the lowest sensitivity observed for RSV (41.5% [95%CI: 26.2 - 56.8]). Higher sensitivities were observed for samples with high viral loads (Ct < 20) and decrease with low viral loads. The specificity for SARS-CoV-2, RSV and Influenza A and B was >95%.

CONCLUSIONS: The Fluorecare® combo antigenic presents satisfying performance in real-life clinical setting for Influenza A and B in samples with high viral load. This could be useful to allow a rapid (self-)isolation as the transmissibility of these viruses increase with the viral load. According to our results, its use to rule-out SARS-CoV-2 and RSV infection is not sufficient.

langue originale	Anglais
Numéro d'article	105419
Pages (de - à)	105419
journal	Journal of Clinical Virology
Volume	161
Date de mise en ligne précoce	28 févr. 2023
Les DOIs	https://doi.org/10.1016/j.jcv.2023.105419
Etat de la publication	Publié - avr. 2023

SDG des Nations Unies

Ce résultat contribue à ou aux Objectifs de développement durable suivants

Accès au document

10.1016/j.jcv.2023.105419

13886-2023-BayartAccepted author manuscript, 1,17 MBLicense: CC BY-NC-ND

Autres fichiers et liens

Lien vers la publication sur Scopus

Clinical Pharmacology Research Group
Douxfils, J. (Promoteur), Dogne, J.-M. (Promoteur), Musuamba Tshinanu, F. (Promoteur), Masereel, B. (Promoteur), Wieërs, G. (Promoteur), Haguet, H. (Chercheur), RONVAUX, L. (Chercheur), Donis, N. (Chercheur), Morimont, L. (Chercheur), Evrard, J. (Chercheur), Siriez, R. (Chercheur), Gillot, C. (Chercheur), FAVRESSE, J. (Chercheur), BOUVY, C. (Chercheur), Djokoto, H. (Chercheur), Didembourg, M. (Chercheur), David, C. (Rôle de support), Melchionda, S. (Rôle de support), Maloteau, V. (Technicien), Boucher, A.-Y. (Technicien), Devel, P. (Technicien), Modaffari, E. (Technicien), Vandeputte, M. (Technicien), De Messemaeker, A. (Secrétaire), Decarpentrie, J. (Chercheur), Vassart, J. (Chercheur) & De Groote, A. (Chercheur)
1/04/22 → …
Projet: Axe de recherche
The COVILAB project : Clinical laboratory investigations related to COVID-19
Douxfils, J. (Promoteur), Dogne, J.-M. (Co-Promoteur), FAVRESSE, J. (Co-investigateur), Tre-Hardy, M. (Co-investigateur), Mullier, F. (Co-investigateur), Haguet, H. (Chercheur), Hardy, M. (Chercheur), Melchionda, S. (Chercheur), BOUVY, C. (Chercheur), Morimont, L. (Chercheur), Gillot, C. (Chercheur), Djokoto, H. (Chercheur), Alpan, L. (Technicien), Devel, P. (Technicien), Modaffari, E. (Technicien) & Maloteau, V. (Technicien)
13/03/20 → …
Projet: Recherche

Data on COVID-19 Detailed by Researchers at University of Namur (Clinical Performance Evaluation of the Fluorecare? Sars-cov-2 & Influenza A/b & Rsv Rapid Antigen Combo Test In Symptomatic Individuals)
Dogne, J.-M. & Douxfils, J.
28/04/23
1 élément de Couverture média
Presse/Médias: Commentaire d'expert

Contient cette citation

@article{0cdbf9fc22af473496b0eaa81d1931cd,

title = "Clinical performance evaluation of the Fluorecare{\textregistered} SARS-CoV-2 & Influenza A/B & RSV rapid antigen combo test in symptomatic individuals",

abstract = "BACKGROUND: A SARS-CoV-2+Flu A/B+RSV Combo Rapid test may be more relevant than Rapid Antigen Diagnostic (RAD) tests targeting only SARS-CoV-2 since we are facing a concurrent circulation of these viruses during the winter season.OBJECTIVES: To assess the clinical performance of a SARS-CoV-2+Flu A/B+RSV Combo test in comparison to a multiplex RT-qPCR.STUDY DESIGN: Residual nasopharyngeal swabs issued from 178 patients were included. All patients, adults and children, were symptomatic and presented at the emergency department with flu-like symptoms. Characterization of the infectious viral agent was done by RT-qPCR. The viral load was expressed as cycle threshold (Ct). Samples were then tested using the multiplex RAD test Fluorecare {\textregistered}ฏ SARS-CoV-2 & Influenza A/B & RSV Antigen Combo Test. Data analysis was carried out using descriptive statistics. RESULTS: The sensitivity of the test varies according to the virus, with the highest sensitivity observed for Influenza A (80.8.% [95%CI: 67.2 - 94.4]) and the lowest sensitivity observed for RSV (41.5% [95%CI: 26.2 - 56.8]). Higher sensitivities were observed for samples with high viral loads (Ct < 20) and decrease with low viral loads. The specificity for SARS-CoV-2, RSV and Influenza A and B was >95%.CONCLUSIONS: The Fluorecare{\textregistered} combo antigenic presents satisfying performance in real-life clinical setting for Influenza A and B in samples with high viral load. This could be useful to allow a rapid (self-)isolation as the transmissibility of these viruses increase with the viral load. According to our results, its use to rule-out SARS-CoV-2 and RSV infection is not sufficient.",

keywords = "Antigen, Combo, Influenza, Multiplex, RAD, RSV, SARS-CoV-2",

author = "Jean-Louis Bayart and Constant Gillot and Jean-Michel Dogn{\'e} and Gatien Roussel and Val{\'e}rie Verbelen and Julien Favresse and Jonathan Douxfils",

note = "Publisher Copyright: {\textcopyright} 2023 Elsevier B.V.",

year = "2023",

month = apr,

doi = "10.1016/j.jcv.2023.105419",

language = "English",

volume = "161",

pages = "105419",

journal = "Journal of Clinical Virology",

issn = "1386-6532",

publisher = "Elsevier",

}

Clinical performance evaluation of the Fluorecare® SARS-CoV-2 & Influenza A/B & RSV rapid antigen combo test in symptomatic individuals. / Bayart, Jean-Louis; Gillot, Constant ; Dogné, Jean-Michel et al.
Dans: Journal of Clinical Virology, Vol 161, 105419, 04.2023, p. 105419.

Résultats de recherche: Contribution à un journal/une revue › Article › Revue par des pairs

TY - JOUR

T1 - Clinical performance evaluation of the Fluorecare® SARS-CoV-2 & Influenza A/B & RSV rapid antigen combo test in symptomatic individuals

AU - Bayart, Jean-Louis

AU - Gillot, Constant

AU - Dogné, Jean-Michel

AU - Roussel, Gatien

AU - Verbelen, Valérie

AU - Favresse, Julien

AU - Douxfils, Jonathan

PY - 2023/4

Y1 - 2023/4

N2 - BACKGROUND: A SARS-CoV-2+Flu A/B+RSV Combo Rapid test may be more relevant than Rapid Antigen Diagnostic (RAD) tests targeting only SARS-CoV-2 since we are facing a concurrent circulation of these viruses during the winter season.OBJECTIVES: To assess the clinical performance of a SARS-CoV-2+Flu A/B+RSV Combo test in comparison to a multiplex RT-qPCR.STUDY DESIGN: Residual nasopharyngeal swabs issued from 178 patients were included. All patients, adults and children, were symptomatic and presented at the emergency department with flu-like symptoms. Characterization of the infectious viral agent was done by RT-qPCR. The viral load was expressed as cycle threshold (Ct). Samples were then tested using the multiplex RAD test Fluorecare ®ฏ SARS-CoV-2 & Influenza A/B & RSV Antigen Combo Test. Data analysis was carried out using descriptive statistics. RESULTS: The sensitivity of the test varies according to the virus, with the highest sensitivity observed for Influenza A (80.8.% [95%CI: 67.2 - 94.4]) and the lowest sensitivity observed for RSV (41.5% [95%CI: 26.2 - 56.8]). Higher sensitivities were observed for samples with high viral loads (Ct < 20) and decrease with low viral loads. The specificity for SARS-CoV-2, RSV and Influenza A and B was >95%.CONCLUSIONS: The Fluorecare® combo antigenic presents satisfying performance in real-life clinical setting for Influenza A and B in samples with high viral load. This could be useful to allow a rapid (self-)isolation as the transmissibility of these viruses increase with the viral load. According to our results, its use to rule-out SARS-CoV-2 and RSV infection is not sufficient.

AB - BACKGROUND: A SARS-CoV-2+Flu A/B+RSV Combo Rapid test may be more relevant than Rapid Antigen Diagnostic (RAD) tests targeting only SARS-CoV-2 since we are facing a concurrent circulation of these viruses during the winter season.OBJECTIVES: To assess the clinical performance of a SARS-CoV-2+Flu A/B+RSV Combo test in comparison to a multiplex RT-qPCR.STUDY DESIGN: Residual nasopharyngeal swabs issued from 178 patients were included. All patients, adults and children, were symptomatic and presented at the emergency department with flu-like symptoms. Characterization of the infectious viral agent was done by RT-qPCR. The viral load was expressed as cycle threshold (Ct). Samples were then tested using the multiplex RAD test Fluorecare ®ฏ SARS-CoV-2 & Influenza A/B & RSV Antigen Combo Test. Data analysis was carried out using descriptive statistics. RESULTS: The sensitivity of the test varies according to the virus, with the highest sensitivity observed for Influenza A (80.8.% [95%CI: 67.2 - 94.4]) and the lowest sensitivity observed for RSV (41.5% [95%CI: 26.2 - 56.8]). Higher sensitivities were observed for samples with high viral loads (Ct < 20) and decrease with low viral loads. The specificity for SARS-CoV-2, RSV and Influenza A and B was >95%.CONCLUSIONS: The Fluorecare® combo antigenic presents satisfying performance in real-life clinical setting for Influenza A and B in samples with high viral load. This could be useful to allow a rapid (self-)isolation as the transmissibility of these viruses increase with the viral load. According to our results, its use to rule-out SARS-CoV-2 and RSV infection is not sufficient.

KW - Antigen

KW - Combo

KW - Influenza

KW - Multiplex

KW - RAD

KW - RSV

KW - SARS-CoV-2

UR - http://www.scopus.com/inward/record.url?scp=85150377001&partnerID=8YFLogxK

U2 - 10.1016/j.jcv.2023.105419

DO - 10.1016/j.jcv.2023.105419

M3 - Article

C2 - 36905798

SN - 1386-6532

VL - 161

SP - 105419

JO - Journal of Clinical Virology

JF - Journal of Clinical Virology

M1 - 105419

ER -

Clinical performance evaluation of the Fluorecare® SARS-CoV-2 & Influenza A/B & RSV rapid antigen combo test in symptomatic individuals

Résumé

SDG des Nations Unies

Accès au document

Autres fichiers et liens

Empreinte digitale

Projets

Clinical Pharmacology Research Group

The COVILAB project : Clinical laboratory investigations related to COVID-19

Presse/médias

Data on COVID-19 Detailed by Researchers at University of Namur (Clinical Performance Evaluation of the Fluorecare? Sars-cov-2 & Influenza A/b & Rsv Rapid Antigen Combo Test In Symptomatic Individuals)

Contient cette citation